

2

Docket No. NPB-100D5

Serial No. 09/970,558

1 306. The pharmaceutical paclitaxel composition of claim 305, further comprising
2 ethanol.

1 307. The pharmaceutical paclitaxel composition of claim 305, wherein said acid is an
2 organic acid.

1 308. The pharmaceutical paclitaxel composition of claim 305, wherein said acid is a
2 mineral acid.

1 309. The pharmaceutical paclitaxel composition of claim 307, wherein said acid is citric
2 acid.

a'cont
1 310. The pharmaceutical paclitaxel composition of claim 309, wherein said citric acid
2 is monohydrous.

1 311. The pharmaceutical paclitaxel composition of claim 309, wherein the citric acid is
2 hydrous.

1 312. The pharmaceutical paclitaxel composition of claim 309, wherein the citric acid is
2 anhydrous.

1 313. The pharmaceutical paclitaxel composition of claim 307, wherein said acid is acetic
2 acid.

1 314. The pharmaceutical paclitaxel composition of claim 306, wherein said acid is an
2 organic acid.

1 315. The pharmaceutical paclitaxel composition of claim 306, wherein said acid is a
2 mineral acid.

3

Docket No. NPB-100D5
Serial No. 09/970,558

1 316. The pharmaceutical paclitaxel composition of claim 314, wherein said acid is citric
2 acid.

1 317. The pharmaceutical paclitaxel composition of claim 316, wherein said citric acid
2 is monohydrous.

1 318. The pharmaceutical paclitaxel composition of claim 316, wherein the citric acid is
2 hydrous.

1 319. The pharmaceutical paclitaxel composition of claim 316, wherein the citric acid is
2 anhydrous.

1 320. The pharmaceutical paclitaxel composition of claim 314, wherein said acid is acetic
2 acid.

1 321. An improved pharmaceutical paclitaxel composition, said composition comprising
2 as ingredients paclitaxel;
3 polyethoxylated castor oil; and ethanol;
4 the improvement comprising an acid mixed with said ingredients such that the stability
5 of the paclitaxel composition is improved as compared to the same paclitaxel composition
6 without said acid; and
7 said improved paclitaxel composition being such that at least 97.5% of the paclitaxel
8 potency is retained when said composition is stored at 40° C for 7 days.

1 322. The improved pharmaceutical paclitaxel composition of claim 321, said
2 composition being substantially free of water.

1 323. The improved pharmaceutical paclitaxel composition of claim 322, wherein said
2 acid is an organic acid.

1 324. The improved pharmaceutical paclitaxel composition of claim 322, wherein said
2 acid is a mineral acid.

1 325. The improved pharmaceutical paclitaxel composition of claim 323, wherein said
2 acid is citric acid.

1 326. The improved pharmaceutical paclitaxel composition of claim 325, wherein said
2 citric acid is monohydrous.

1 327. The improved pharmaceutical paclitaxel composition of claim 325, wherein the
2 citric acid is hydrous.

1 328. The improved pharmaceutical paclitaxel composition of claim 325, wherein the
2 citric acid is anhydrous.

1 329. The improved pharmaceutical paclitaxel composition of claim 323, wherein said
2 acid is acetic acid.

1 330. A pharmaceutical paclitaxel composition consisting essentially of:
2 paclitaxel;
3 polyethoxylated castor oil;
4 ethanol; and
5 an acid;
6 said acid being in sufficient amount to confer improved paclitaxel stability to said
7 composition as compared to the paclitaxel stability in the same composition without said acid;
8 said pharmaceutical paclitaxel composition being substantially free of water; and
9 said composition being such that at least 97.5% of the paclitaxel potency is retained when
10 said composition is stored at 40° C for 7 days.

1 331. The pharmaceutical paclitaxel composition of claim 330, wherein said acid is an
2 organic acid.

1 332. The pharmaceutical paclitaxel composition of claim 330, wherein said acid is a
2 mineral acid.

1 333. The pharmaceutical paclitaxel composition of claim 331, wherein said acid is citric
2 acid.

1 334. The pharmaceutical paclitaxel composition of claim 333, wherein said citric acid
2 is monohydrous.

1 335. The pharmaceutical paclitaxel composition of claim 333, wherein the citric acid is
2 hydrous.

1 336. The pharmaceutical paclitaxel composition of claim 333, wherein the citric acid is
2 anhydrous.

1 337. The pharmaceutical paclitaxel composition of claim 332, wherein said acid is acetic
2 acid.

1 338. An article of manufacture comprising a sealed container and a pharmaceutical
2 paclitaxel composition disposed within said sealed container, said pharmaceutical paclitaxel
3 composition being substantially free of water and comprising:
4 paclitaxel;
5 polyethoxylated castor oil;
6 ethanol; and
7 an acid;
8 said acid being in sufficient amount to confer improved paclitaxel stability to said
9 composition as compared to the same composition without said acid; and

10 said composition being such that at least 97.5% of the paclitaxel potency is retained when
11 said composition is stored at 40° C for seven days.

1 339. The article of manufacture of claim 338, wherein said acid is an organic acid.

1 340. The article of manufacture of claim 338, wherein said acid is a mineral acid.

1 341. The article of manufacture of claim 339, wherein said acid is acetic acid.

1 342. The article of manufacture of claim 339, wherein said acid is citric acid.

1 343. The article of manufacture of claim 342, wherein said citric acid is anhydrous.

1 344. The article of manufacture of claim 342, wherein said citric acid is monohydrous.

1 345. The article of manufacture of claim 342, wherein said citric acid is hydrous.

1 346. An article of manufacture produced by the process of:

2 (a) obtaining a sealable container;

3 (b) obtaining a pharmaceutical formulation consisting essentially of paclitaxel,
4 polyethoxylated castor oil, ethanol, and an acid; said acid being in sufficient amount such that
5 the paclitaxel stability in said formulation is improved as compared to the stability of paclitaxel
6 in the same formulation without said acid, and said acid-containing formulation being such that
7 at least 97.5% of the paclitaxel potency is retained when said formulation is stored at 40° C for
8 seven days;

9 (c) placing said pharmaceutical formulation in said sealable container;

10 (d) sealing said sealable container; and

11 (e) storing said pharmaceutical formulation in said sealed container for at least seven
12 days.

1 347. The article of manufacture of claim 346, wherein said acid is an organic acid.

1 ~~348. The article of manufacture of claim 346, wherein said acid is a mineral acid.~~

1 349. The article of manufacture of claim 347, wherein said acid is acetic acid.

1 350. The article of manufacture of claim 347, wherein said acid is citric acid.

1 351. The article of manufacture of claim 350, wherein said citric acid is anhydrous.

1 352. The article of manufacture of claim 350, wherein said citric acid is monohydrous.

1 353. The article of manufacture of claim 350, wherein said citric acid is hydrous.

1 354. A pharmaceutical paclitaxel composition which is at least 7 days old, consisting

2 essentially of:

3 paclitaxel;

4 polyethoxylated castor oil;

5 ethanol; and

6 an acid;

7 said acid being in sufficient amount such that the paclitaxel stability of said composition

8 is improved as compared to the paclitaxel stability of an identical composition without said acid;

9 and

10 said at least 7-day-old composition being such that at least 97.5% of the original

11 paclitaxel potency is retained.

1 355. A pharmaceutical paclitaxel composition of claim 354, wherein said acid is an

2 organic acid.

cont

1 356. A pharmaceutical paclitaxel composition of claim 354, wherein said acid is a
2 mineral acid.

1 357. A pharmaceutical paclitaxel composition of claim 355, wherein said acid is acetic
2 acid.

1 358. A pharmaceutical paclitaxel composition of claim 355, wherein said acid is citric
2 acid.

1 359. A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is
2 anhydrous.

1 360. A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is
2 monohydrous.

1 361. A pharmaceutical paclitaxel composition of claim 358, wherein said citric acid is
2 hydrous.

1 362. A method for formulating a pharmaceutical paclitaxel composition such that the
2 paclitaxel does not readily degrade, comprising

3 obtaining a composition consisting essentially of paclitaxel, polyethoxylated castor oil,
4 ethanol, and an acid, said acid being in sufficient amount such that the paclitaxel stability of said
5 composition is improved as compared to the paclitaxel stability of an identical composition
6 without said acid; and

7 sealing said acid-containing paclitaxel composition in a container, wherein said
8 pharmaceutical acid-containing paclitaxel composition retains at least 97.5% of the original
9 paclitaxel potency when stored at 40° C for 7 days.

1 363. The method of claim 362, wherein said acid is an organic acid.

9

Docket No. NPB-100D5
Serial No. 09/970,558

1 364. The method of claim 362, wherein said acid is a mineral acid.

1 365. The method of claim 363, wherein said acid is acetic acid.

1 366. The method of claim 363, wherein said acid is citric acid.

1 367. The method of claim 366, wherein said citric acid is anhydrous.

1 368. The method of claim 366, wherein said citric acid is monohydrous.

1 369. The method of claim 366, wherein said citric acid is hydrous.
